Anika Therapeutics (ANIK) director purchases 2,000 common shares in market buys

Rhea-AI Filing Summary

Anika Therapeutics, Inc. director Gary P. Fischetti reported open-market purchases of company stock. On August 3 and 4, 2026, he bought 1,000 shares of Common Stock on each date at per-share prices of $20.745 and $20.315, respectively, for a total of 2,000 shares acquired directly.

Insider Trade Summary

Net Buyer: 2,000 shares

Net Buy 2 txns

Insider Fischetti Gary P

Role Director

Bought 2,000 shs ($41K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,000	$20.315	$20K
Purchase	Common Stock	1,000	$20.745	$21K

Holdings After Transaction: Common Stock — 54,015 shares (Direct)

Key Figures

Shares purchased 2026-08-03: 1,000 shares Shares purchased 2026-08-04: 1,000 shares Total shares purchased: 2,000 shares +2 more

5 metrics

Shares purchased 2026-08-03 1,000 shares Common Stock bought at $20.745 per share on 2026-08-03

Shares purchased 2026-08-04 1,000 shares Common Stock bought at $20.315 per share on 2026-08-04

Total shares purchased 2,000 shares Aggregate Common Stock acquired across both reported transactions

Purchase price 2026-08-03 $20.745 per share Per-share price for 1,000-share Common Stock purchase on 2026-08-03

Purchase price 2026-08-04 $20.315 per share Per-share price for 1,000-share Common Stock purchase on 2026-08-04

Key Terms

Form 4, non-derivative, open market or private transaction

3 terms

Form 4 regulatory

"Reported insider transactions are disclosed on SEC Form 4."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

non-derivative financial

"Each transaction is classified as a non-derivative security transaction."

open market or private transaction financial

"The code P indicates an open market or private transaction purchase."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/05/2026 - 04:30 PM Accepted by SEC EDGAR 08/05/2026 - 04:30 PM Learn about SEC filing dates

FAQ

What did Anika Therapeutics (ANIK) director Gary P. Fischetti report in this Form 4?

Gary P. Fischetti reported buying 2,000 shares of Anika Therapeutics Common Stock. The Form 4 lists two open-market purchase transactions of 1,000 shares each, executed on August 3 and 4, 2026, at prices just above $20 per share.

How many ANIK shares did Gary P. Fischetti buy and on which dates?

He purchased 2,000 ANIK shares in total. The transactions were split into two equal buys of 1,000 shares each, executed on August 3, 2026 and August 4, 2026, as reported in the Form 4 filing.

At what prices were the ANIK common shares purchased in this Form 4?

The reported purchases were made at $20.745 per share on August 3, 2026 and $20.315 per share on August 4, 2026. Both transactions involved Anika Therapeutics Common Stock acquired in open-market purchases.

Were Gary P. Fischetti’s ANIK share purchases reported as direct or indirect ownership?

Both transactions are reported as direct ownership. The Form 4 lists the ownership code as “D” for each 1,000-share purchase, indicating the shares are held directly rather than through a trust, fund, or other indirect entity.

How many ANIK share purchase transactions are disclosed in this Form 4?

The Form 4 discloses two separate purchase transactions. Each transaction involved 1,000 shares of Anika Therapeutics Common Stock bought in the open market on consecutive days, for a combined total of 2,000 shares acquired.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fischetti Gary P

(Last) (First) (Middle)

C/O ANIKA THERAPEUTICS, INC.

32 WIGGINS AVENUE

(Street)

BEDFORD MASSACHUSETTS 01730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Anika Therapeutics, Inc. [ ANIK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/03/2026		P		1,000	A	$20.745	53,015	D
Common Stock	08/04/2026		P		1,000	A	$20.315	54,015	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Gary P. Fischetti	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)